Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.

9068Background: AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR T790M-mutant non–small cell lung cancer (NS...